Sunmax Biotechnology Co., Ltd. Stocks

NT$ 388.5Last Updated 28.04.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

NT$ 670.10M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 388.5
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes; and dermal fillers, such as Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant with lidocaine, and Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge, extraction sockets, and periodontology. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Tainan City, Taiwan.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks